Neo-T: Autologous Mutant Neoantigen-Specific, TCR-Engineered T Cells For Adoptive Cellular Therapy



    • Selecting appropriate antigens on cancers is critical for development of T cell-based cellular therapies. Because of the enormous number/diversity of cancers it is impossible to clearly identify tumor antigens that can function as targets across different tumor entities and large groups of patients. 
    • Inventors at the University of Chicago have developed a proprietary platform called “Neo-T” allowing the use of mutant neoantigens from an individual’s own cancer cells as a target structure for adoptively transferred T cells. The technology is based on the selection of a suitable pair of T cell receptors (TCRs) that can recognize neoantigens presented by patient MHC molecules.
    • To achieve tumor eradication, one of the two TCRs must recognize a neoantigen in the context of an MHC class I molecule, and the other in the context of an MHC class II molecule. To increase the number/availability of neoantigen-specific T cells in a patient before TCR isolation, a vaccination strategy was developed using non-malignant surrogate cancer cells (SCCs) from the patient. Proof-of-principle studies demonstrated complete eradication of large and long-established solid tumors in mice.


    Neo-T therapy’s 3-step process: identification of mutant neoantigens and production of SCCs, isolation of neoantigen-specific T cells from patient tumor-infiltrating lymphocytes or peripheral blood (SCC vaccination may be required), and adoptive therapy using T cells created with neoantigen-specific TCRs. 



    • Universal, personalized T-cell cancer treatment

    • Selection of optimal TCRs in the context of both MHC I & II

    • Enhanced safety and minimized unpredictable cross-reactivity are eliminated which may be encountered when using TCRs from other sources



    • Adoptive T cell therapies for cancer

    • Cancer vaccine

    • Preclinical – in vivo



    Reference ID

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.